Los Alamos Hospital ER during Hep C research
Syndromic Disease Surveillance
Alan P. Zelicoff, MD
Mike Westerfield, Jim Linsday
and the talented staff of ARES Corporation

A practical approach for the early detection of novel diseases

Currently, diseases of public health importance are reported once a diagnosis is in hand, generally requiring laboratory testing. However, even with the best of laboratory reporting, the data is received well after the patient is into the clinical course of illness (and infectiousness to others if the disease happens to be communicable).  Alternatively, in the setting of a truly novel disease (such as SARS, monkeypox, Hantavirus, cryptosporidiosis – all of which have unexpectedly stuck in the United States), laboratory resources, in general, do not permit diagnosis since testing protocols and reagents are not available for new disease entities.

Once public health has received enough information to perform an analysis, it has few—if any—channels for rapidly communicating information to clinicians and other end-users of the data they have assembled and analyzed.  Finally, most existing syndromic surveillance systems collect data only from hospitals and do not collect or use veterinary data.  Since the vast majority of serious infectious diseases affecting the human population are zoonotic in origin (including, for example, novel subtypes or influenza), robust human disease surveillance requires equally robust veterinary surveillance. 

As but one more example that underscores the latter point: the hemorrhagic E.Coli outbreak of 2006 in the US went for many weeks before disparate public health entities even became aware of its existence.  As hundreds of people were hospitalized across the country with life-threatening illness (resulting in at least 6 deaths though the true mortality figures may never be known due to the complete lack of a systematic, affordable disease surveillance system across the US), more time passed as California agricultural officials struggled to find the source of the outbreak.  Most of us would regard this as a public health failure, and in any case unacceptable in the 21st century when rapid communication among physicians, veterinarians, wild-life observers and public health officials is not only possible but now proven with a disease reporting system called SYRIS.

Dr. Zelicoff is a former Senior Scientist at Sandia National Laboratories (http://www.sandia.gov), where he became internationally known for his work on counter-terrorism, specifically as applied to the problem of biological weapons.  He is the inventor of the Sydrome Reporting Information System (SYRIS) which is being tested in multiple public health offices around the US.  SYRIS gathers clinical data from a wide variety of sources and medical communities around the country, including from: physicians, veterinarians, animal control and environmental health officials, coroner's offices, laboratories, school nurses, and EMS professionals (see on-line video below).  The software includes simple but highly flexible GIS software implementing a mapping-based (or "visual") approach to data analysis as well as standard statistical techniques so that public health officials can rapidly evaluate data and provide near real-time alerts and advice to clinicians. 

SYRIS can also be used as an emergency management tool in the setting of terrorist attack with non-conventional weapons.  Several states are currently evaluating SYRIS for both this use and routine public health practice.  The Center for the Study of Bioterrorism and Emerging Diseases at St. Louis University is currently evaluating SYRIS as well.  The Center is funded, in part, by a bioterrorism research grant from the Centers for Disease Control (www.cdc.gov).

SYRIS code is copyrighted and owned by ARES Corporation (with whom Dr. Zelicoff is under contract as a Senior Scientific Consultant; please note in the interest of full disclosure that Zelicoff has NO financial interest in either ARES Corporation OR SYRIS.  He is under contract to develop, improve and promote disease surveillance software systems for ARES). 

You may request an on-line demo of SYRIS by contacting Dr. Zelicoff at ARES' Albuquerque office:
  • by e-mail at: azelicoff@arescorporation.com
  • by phone: 1-505-272-7102 
He will arrange to personally demonstrate the software and discuss its implementation in public health offices and clinics.  You can read the SYRIS Manual on the main SYRIS web page (see left hand side of the web page) and several background documents on SYRIS including a summary of the experience in West Texas, an epidemiologically complicated, mixed urban and rural area that is also near the Mexico border.   Documentation available for public use includes:
A detailed paper on the four-year experience with SYRIS is available here (written 6/06 and being revised for submission to a refereed journal.)

Several video demonstrations of SYRIS (in Windows Media Player or .wmv format) can be seen by clicking on the links below:

Feel free to contact Dr. Zelicoff with any questions you may have. E-mail is often the easiest way to reach him, and he responds quickly (even on weekends and holidays).


My special thanks to Jim Stadnyck of Point of View Photography for design of this webpage and much inspiration.

[Webpage last updated 2/8/07]

Click here for a paper describing SYRIS use in public health

Phone: (505) 255-6908
FAX: (509) 753-4906
zalan8587@qwest.net

ICQ# 21627838

AIM or iChat Screen name: apzelic

Skype name: apzelic
Resume

Al Zelicoff's Business and Work Interests

(and an index to this site):

Scientific and Medical-Legal Review of New Mexico:

  • Medical Malpractice and Accident Reconstuction analysis
  • Public Health Consulting

Syndrome-based Disease Surveillance (this page): information technology tools to help bring public health and medicine into the 21st Century easily and inexpensively.  

Environmentally Friendly Energy Systems

  • residential energy conservation and renewable energy system designs for your home or small buiness

Expert Witness and Analysis: on thee abusive use of polygraphs and random drug testing in Employee Screening.